OXiGENE to Present at Rodman and Renshaw, Lazard Healthcare Conferences
WALTHAM, Mass., Nov. 6, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, announced today that CEO John
Kollins will present a corporate overview and update at the Rodman and Renshaw
10th Annual Healthcare Conference on Monday, November 10th, at 4:05 p.m. EST
(1:05 p.m. PST), in the Palace Hotel in New York City, N.Y.
Mr. Kollins will also present a corporate overview and update at the Lazard
Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18th, at
2:10 p.m. EST (11:10 a.m. PST), in the St. Regis Hotel in New York City, N.Y.
A live and archived webcast of each presentation can be accessed for 30 days
following the presentations by clicking on the Investor Center tab at
www.oxigene.com.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing VDAs that selectively disrupt abnormal blood vessels associated with
solid tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property and therapeutic development expertise to
bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: OXiGENE, Inc.
Investor and Media Contact
Michelle Edwards, Investor Relations
415-315-9413
medwards@oxigene.com
OXiGENE to Present at Rodman and Renshaw, Lazard Healthcare Conferences
| Source: Oxigene, Inc.